期刊
NEUROLOGY
卷 66, 期 12, 页码 1824-1829出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000221672.01272.ba
关键词
-
Objective: To investigate if Helicobacter pylori (HP) eradication could make an effective and long-lasting improvement in the pharmacokinetic and clinical response to L-dopa in patients with Parkinson disease (PD) and motor fluctuations. Methods: In a group of 34 HP-infected, motor-fluctuating patients with PD, the short-term (1-week) and long-term (3-month) beneficial effect of HP eradication (n=17) was investigated in a double-blind fashion in comparison with a generic antioxidant treatment (n=17), by means of pharmacokinetic, clinical, and gastrointestinal assessments. Results were compared with placebo treatment. Results: Differently from the antioxidant-treated patients, the HP-eradicated patients showed a significant increase of L-dopa absorption, which was coupled with a significant improvement of clinical disability and with a prolonged on-time duration, whereas gastritis/duodenitis scores significantly decreased in line with a better L-dopa pharmacokinetics. Conclusions: These data demonstrate a reversible Helicobacter pylori (HP)-induced interference with L-dopa clinical response related to the impaired drug absorption, probably due to active gastroduodenitis. Therefore, the authors suggest that HP eradication may improve the clinical status of infected patients with Parkinson disease and motor fluctuations by modifying L-dopa pharmacokinetics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据